Los accionistas planean reducir sus participaciones de manera "limpia", lo que hizo desplomarse el precio de las acciones, y los accionistas relacionados con Zhaoyan New Drug están ocupados ajustando sus planes de reducción de participación.

就在前一日，昭衍新药发布公告称，公司股东顾晓磊及其一致行动人顾美芳拟自减持计划公告之日起3个交易日后的3个月内，通过上交所以集中竞价的方式分别减持2042.05万股、1032.2万股，合计减持3074.25万股，占公司当前总股本的4.1%。
As of the announcement date, 顾晓磊、顾美芳分别持有公司A股股份2042.05万股、1032.2万股，持股比例分别约为2.73%、1.38%。
This also means that the aforementioned shareholders intended to “liquidate” their holdings of the company’s A shares.

受这一消息影响，3月17日，昭衍新药A股、H股双双大跌，其中A股更是以跌停收盘，报跌停价29.32元/股，跌幅为10.01%。
On the H-share side, 昭衍新药大幅收跌11.73%，收盘价为16.78港元/股。

公告显示，昭衍新药此次拟减持的两名股东均为公司首发股东，股份来源为首发前限售股份及公司资本公积金转增股份等，拟减持原因系自身资金需求。
The announcement indicates that the two shareholders planning to reduce their holdings are both original shareholders of the company, with shares sourced from pre-IPO restricted shares and shares converted from the company’s capital reserve, with the reason for the reduction being personal funding needs.

在奥优国际董事长张玥看来，此次拟减持计划的调整属于降温、缓释动作，通过缩减规模、搭配对盘面冲击更小的大宗交易方式，意在稳定预期、降低抛压。
However, it still constitutes a significant reduction, and has not been canceled or postponed; it has merely reduced the intensity of the impact, without completely eliminating the negative signals brought by the reduction, and the subsequent price movement will depend on the company’s fundamentals and industry conditions.

实际上，这不是近期昭衍新药首度披露股东拟进行减持的公告。
In fact, this is not the first time recently that 昭衍新药 has disclosed a shareholder’s intent to reduce holdings.
去年底，公司实际控制人之一周志文披露了减持计划，拟减持不超过公司当时总股本的2%。
At the end of last year, one of the company’s actual controllers, 周志文, disclosed a reduction plan to reduce no more than 2% of the company’s then total share capital.
截至1月29日，周志文以大宗交易及集中竞价交易的方式减持公司A股股份1497.9万股，减持比例约为2%，并决定提前终止减持计划。
As of January 29, 周志文 reduced his holdings of the company’s A shares by 14.979 million shares through block trades and centralized bidding, accounting for about 2%, and decided to terminate the reduction plan early.

在二级市场上，2025年以来，昭衍新药A股股价整体走高，后复权形式下涨幅超七成，不过今年1月中旬触及阶段性高点以来，昭衍新药股价开始持续回调。
In the secondary market, since 2025, the share price of 昭衍新药 has risen overall, with an increase of over 70% in post-adjustment terms; however, since reaching a peak in mid-January of this year, the stock price of 昭衍新药 has begun to decline continuously.

值得一提的是，业绩方面，昭衍新药交出了一份业绩大增的“成绩单”。
It is worth mentioning that in terms of performance, 昭衍新药 has delivered a “report card” of significantly increased results.
公司2025年业绩预告显示，预计2025年归属净利润约2.33亿元到3.49亿元，同比增加约214%到371%。
The company’s 2025 performance forecast indicates that it expects a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, an increase of approximately 214% to 371% year-on-year.
昭衍新药表示，报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩作出积极贡献。
昭衍新药 stated that during the reporting period, the rise in market prices of biological assets, combined with its own natural growth and appreciation, drove positive changes in its fair value, contributing positively to the company’s performance.
此前北京商报记者曾报道，2025年底实验猴价格迎来暴涨，素有“猴茅”之称的昭衍新药也因此获益。
Previously, Beijing Business Daily reported that the price of experimental monkeys surged at the end of 2025, benefiting 昭衍新药, known as “Monkey Mao.”

不过，昭衍新药也提到，报告期内，公司实验室继续保持良好稳定的运营状态，但受前期行业竞争剧烈的滞后影响，本报告期履约合同的收入和毛利率同比降低，实验室服务业务利润贡献下降。
However, 昭衍新药 also mentioned that during the reporting period, the company’s laboratories maintained a good and stable operational status, but due to the lagging effects of intense industry competition, the revenue and gross margin from performance contracts decreased year-on-year, leading to a decline in profit contribution from laboratory service business.

针对公司相关问题，北京商报记者尝试联系昭衍新药相关负责人进行采访，不过截至发稿未收到回复。
Regarding relevant issues of the company, Beijing Business Daily attempted to contact the relevant person in charge of 昭衍新药 for an interview, but as of the time of publication, no response had been received.

文/北京商报记者 丁宁
By/Beijing Business Daily reporter 丁宁

海量资讯、精准解读，尽在新浪财经APP
A wealth of information and precise interpretation can be found in the Sina Finance APP.